Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland

Critchlow, S. et al. (2023) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, (doi: 10.2217/fon-2023-0372) (PMID:37529943) (Early Online Publication)

Abstract

Aim: The cost–effectiveness of avelumab first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma in Scotland was assessed. Materials & methods: A partitioned survival model was developed comparing avelumab plus best supportive care (BSC) versus BSC alone, incorporating JAVELIN Bladder 100 trial data, costs from national databases and published literature and clinical expert validation of assumptions. Incremental cost–effectiveness ratio (ICER) was estimated using lifetime costs and quality-adjusted life-years (QALY). Results: Avelumab plus BSC had incremental costs of £9446 and a QALY gain of 0.63, leading to a base-case (deterministic) ICER of £15,046 per QALY gained, supported by robust sensitivity analyses. Conclusion: Avelumab first-line maintenance is likely to be a cost-effective treatment for locally advanced or metastatic urothelial carcinoma in Scotland.

• Item Type: Articles
• Additional Information: This study was sponsored by Merck (CrossRef Funder ID: 10.13039/100009945) and was previously conducted under an alliance between Merck and Pfizer.
• Status: Early Online Publication
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Jones, Professor Robert
• Authors: Critchlow, S., Bullement, A., Crabb, S., Jones, R., Christoforou, K., Amin, A., Xiao, Y., Kapetanakis, V., Benedict, Á., Chang, J., Kearney, M., and Eccleston, A.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
• Journal Name: Future Oncology
• Publisher: Future Medicine
• ISSN: 1479-6694
• ISSN (Online): 1744-8301
• Published Online: 02 August 2023
• Copyright Holders: Copyright © 2023 Anthony Eccleston
• First Published: First published in Future Oncology 2023
• Publisher Policy: Reproduced under a Creative Commons licence